Could therapeutic vaccines treat hard to beat breast cancers?

	Tweet

A comprehensive analysis of nearly 1,600 tumor samples has found that CT-X genes are expressed in nearly half the breast cancers that lack the estrogen receptor (ER). CT-X gene products are the targets of therapeutic cancer vaccines already in phase III clinical trials for lung cancer and melanoma. The study—to be published in the Early Edition of the Proceedings of the National Academy of Sciences this week—was led by the international Ludwig Institute for Cancer Research (LICR).

ER negative breast cancers, which account for a third of all breast cancer cases, are a group of tumors that has a generally poor prognosis and few therapy options. A subgroup of the ER negative group is triple-negative breast cancer (TNBC), which lacks the estrogen, progesterone and HER2 receptors. TNBC is responsible for most of the breast cancers that strike down African American and young women.

In the current study, gene and protein expression studies showed that nearly half of primary ER negative and triple-negative breast cancers express members of either or both the MAGEA and NY-ESO-1/CTAG1B families of CT-X genes. Approximately half of the primary tumor samples from patients with the basal-like form of breast cancer, which is usually ER negative, also expressed either or both of these gene families, and nearly two-thirds of metastases from basal-like tumors also expressed these genes. 

These findings suggest that a therapeutic vaccine combining members of the two CT-X families could be a new therapy approach to filling a critical unmet need.

Dr. Andrew Simpson, LICR scientific director and an author of the study, said that clinical trials based on the findings of the PNAS study could theoretically be initiated in the near future. “Vaccines targeting MAGEA3 are already in phase III trials, and the Cancer Vaccine Collaborative, a partnership between the Ludwig Institute and the Cancer Research Institute, has demonstrated the safety of different forms of the NY-ESO-1 antigen in phase I and II trials in a variety of tumor types.”

According to LICR’s Dr. A. Munro Neville, the senior author of the study, obtaining clinic-grade material for more members of the CT-X families and funding for a clinical trial will be the next steps in determining if therapeutic cancer vaccines can meet a critical need in breast cancer therapy.

CT genes—the X denotes chromosome localization—encode CT antigens, proteins that are recognized by the immune system. Spontaneous immune responses against CT antigens are thought to be a natural form of cancer control and might be the mechanism behind spontaneous remission.

Therapeutic cancer vaccines are being developed to induce, strengthen and/or sustain immune responses against cancer. GlaxoSmithKline (GSK), which licensed MAGEA3 and NY-ESO-1 from LICR, is currently conducting phase III clinical trials of a MAGEA3-based cancer vaccine, or “antigen-specific cancer immunotherapy” (ASCI) in non-small cell lung cancer and melanoma.

###

Contact: Sarah L. White, Ph.D.

917-379-0398
Ludwig Institute for Cancer Research

RELATED STORIES:
New model predicts relapse in early breast cancer patients following endocrine therapy   Big Bias In Who Gets Screened for Breast Cancer   BRCA1 and BRCA2: Cancer Risk and Genetic Testing   NSAIDs could help prevent, treat breast cancer   Breast MRI spots other cancers, may alter treatment plan   Pink Pumps Fight Breast Cancer   MRI ‘best’ for looking at breast cancer and more   HER-2 Status Predicts Success of Chemotherapy in Breast Cancer Treatment   Breast cancer breakthrough as scientists discover faulty gene linked to half of all cases   “Room for improvement” in care after breast cancer   Most breast cancers not linked to ovarian cancer   Cells lining milk ducts hold key to spread of common form of breast cancer   Contrast agent puts new light on diagnosing breast cancer   Hip size of mothers linked to breast cancer in daughters   Nanotube Therapy Takes Aim at Breast Cancer Stem Cells   Red Or White Wine? Both Are Equal in Terms of Breast-Cancer Risk   Mutation quadruples repeat breast cancer risk   Obesity raises overall risk of breast cancer   Noninvasive combination technique may reduce number of breast biopsies   UK, Iceland lead fall in Europe breast cancer deaths   Soy in childhood may reduce breast cancer risk   UT Southwestern launches clinical trial for treatment of breast cancer using CyberKnife

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]